Table S4.
Univariate logistic regression analysis
|
|||
---|---|---|---|
OR | 95% CI | P-value | |
Sex | |||
Male | Reference | ||
Female | 0.620 | 0.283–1.356 | 0.231 |
Age | 0.998 | 0.964–1.033 | 0.916 |
Dose | |||
50 mg | Reference | ||
100 mg | 0.783 | 0.257–2.391 | 0.668 |
150 mg | 0.667 | 0.073–6.111 | 0.720 |
ARBs pretreatment | |||
IRB | Reference | ||
ARBs–IRB switch | 2.507 | 1.088–5.774 | 0.031* |
Diabetic nephropathy | |||
Stage II | 1.009 | 0.429–2.373 | 0.984 |
Stage III | 0.560 | 0.174–1.801 | 0.331 |
Myocardial disease | 0.600 | 0.128–2.823 | 0.518 |
Cerebrovascular disease | 0.600 | 0.128–2.823 | 0.518 |
Arteriosclerosis | ND | 0.000–ND | 0.999 |
Diabetic disease duration | 0.948 | 0.898–1.000 | 0.052 |
History of alcohol intake | 2.364 | 1.044–5.352 | 0.039* |
SBP baseline | 0.980 | 0.927–1.036 | 0.481 |
DBP baseline | 0.965 | 0.905–1.029 | 0.274 |
HbA1c baseline | 0.965 | 0.676–1.379 | 0.847 |
SCr baseline | 1.908 | 0.482–7.553 | 0.357 |
SUA baseline | 1.714 | 1.168–2.515 | 0.006** |
Multiple logistic regression analysis
|
|||
| |||
OR | 95% CI | P-value | |
ARBs–IRB switch | 2.710 | 1.028–7.144 | 0.044* |
SUA baseline | 1.609 | 1.050–2.467 | 0.029* |
History of alcohol intake | 1.576 | 0.612–4.057 | 0.346 |
Notes: SUA decline after 6–12 months was introduced as dependent variable and was coded 1.
P<0.05;
P<0.01.
Abbreviations: ARB, angiotensin II receptor blockers; CI, confidence interval; DBP, diastolic blood pressure; HbA1c, glycated hemoglobin; IRB, irbesartan; OR, odds ratio; ND, not determined; SBP, systolic blood pressure; SCr, serum creatinine; SUA, serum uric acid.